TradeFlare's AI research teams analysed BMY on 5 market nights between May 4, 2026 and September 16, 2026. Each row is that night's verdict, the price that day, and how the price actually moved afterwards — wins and misses alike. Nothing is edited after the fact.
| Date | Verdict | Price | Target / stop | 5 days later | 20 days later | Why (that night) |
|---|---|---|---|---|---|---|
| September 16, 2026 | HOLD | $63.73 | — / — | -3.9% | not yet | Mandatory rules prevent a trade at this time. |
| September 15, 2026 | HOLD | $64.10 | — / — | -2.3% | -11.1% | Fundamentally undervalued with robust free cash flow and strong profitability. |
| September 14, 2026 | HOLD | $63.64 | $66.90 / $59.86 | -2.3% | -10.2% | Bristol Myers Squibb is in a corrective downtrend with key patent expiries ahead, requiring time to establish a stable base near support. |
| September 11, 2026 | HOLD | $63.75 | — / — | -0.9% | -7.1% | The current market and stock-specific factors do not support a buy decision at this time. |
| May 4, 2026 | HOLD | $58.22 | — / — | -3.0% | -5.1% | Successful execution of BMY's growth portfolio strategy. |
Prices are daily closes. "Days later" counts trading days from the close on the day of the call. A HOLD is not a recommendation to buy; only published signals are tracked with a target and stop on the public record. How the research works. Updated October 14, 2026. AI-generated research for educational purposes — it can be wrong and is not financial advice.